Efficacy of intrinsic antitachycardia pacing for ventricular tachycardia refractory to conventional burst pacing: A case series

J Cardiovasc Electrophysiol. 2023 Jan;34(1):225-228. doi: 10.1111/jce.15773. Epub 2022 Dec 16.

Abstract

Intrinsic antitachycardia pacing (iATP) is a novel automated ventricular ATP algorithm that designs ATP sequences based on the analysis of prior failed ATP. Real-world data on the efficacy and safety of iATP are lacking. Among 124 ventricular tachycardia (VT) episodes in 130 consecutive patients (mean age at implantation: 63.8 ± 14.9 years; sex, 95 male and 35 female) for whom implantable cardioverter defibrillator or cardiac resynchronization therapy defibrillator equipped with iATP algorithm was implanted, we investigated the efficacy and safety of iATP for VT refractory to conventional burst pacing. Eight patients had a total of 17 episodes of iATP therapy after failed conventional burst pacing within 11.2 ± 6.6 months of follow-up. Eleven VT episodes (64.7%) in seven patients (87.5%) were successfully terminated by iATP, and only one patient (12.5%) experienced VT acceleration. iATP might be useful for VTs refractory to conventional burst pacing with a low risk of VT acceleration.

Keywords: antitachycardia pacing; cardiac resynchronization therapy defibrillator; implantable cardioverter defibrillator; intrinsic antitachycardia pacing; ventricular tachycardia.

MeSH terms

  • Adenosine Triphosphate
  • Aged
  • Cardiac Pacing, Artificial / adverse effects
  • Cardiac Resynchronization Therapy* / adverse effects
  • Defibrillators, Implantable*
  • Electric Countershock / adverse effects
  • Female
  • Humans
  • Male
  • Middle Aged
  • Tachycardia, Ventricular* / diagnosis
  • Tachycardia, Ventricular* / therapy

Substances

  • Adenosine Triphosphate